f COVID-19: An Updated View as of 2025

References

1. HassineI.H. Covid-19 vaccines and variants of concern: A review.Rev. Med. Virol.2022324e231310.1002/rmv.2313 34755408
   [Google Scholar]
2. WrappD. WangN. CorbettK.S. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.Science20203671260126310.1126/science.abb2507
   [Google Scholar]
3. KowalczukS. BröerA. TietzeN. VanslambrouckJ.M. RaskoJ.E.J. BröerS. A protein complex in the brush-border membrane explains a Hartnup disorder allele.FASEB J.20082282880288710.1096/fj.08‑107300 18424768
   [Google Scholar]
4. ZieglerC.G.K. AllonS.J. NyquistS.K. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues.Cell2020181510161035.e1910.1016/j.cell.2020.04.035 32413319
   [Google Scholar]
5. FiorilloB. MarchianòS. MoracaF. Discovery of bile acid derivatives as potent ACE2 activators by virtual screening and essential dynamics.J. Chem. Inf. Model.202262119620910.1021/acs.jcim.1c01126 34914393
   [Google Scholar]
6. KrauseP.R. FlemingT.R. LonginiI.M. SARS-CoV-2 variants and vaccines.N. Engl. J. Med.2021385217918610.1056/NEJMsr2105280 34161052
   [Google Scholar]
7. XieY. ChoiT. Al-AlyZ. Postacute sequelae of SARS-CoV-2 infection in the pre-delta, delta, and omicron eras.N. Engl. J. Med.2024391651552510.1056/NEJMoa2403211 39018527
   [Google Scholar]
8. BhimrajA. Falck-YtterY. KimA.Y. Clinical practice guideline update by the infectious diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 neutralizing antibody pemivibart for pre-exposure prophylaxis.Clin. Infect. Dis.202410.1093/cid/ciae435 39471458
   [Google Scholar]
9. FiorucciS. UrbaniG. DistruttiE. Bile acids and SARS-CoV-2: Ursodeoxycholic acid as a potential treatment of COVID-19.Recent Adv. Inflamm. Allergy Drug Discov.20231712610.2174/2772270817666230601124326 37264626
   [Google Scholar]
10. FiorucciS. UrbaniG. BiagioliM. SepeV. DistruttiE. ZampellaA. Bile acids and bile acid activated receptors in the treatment of covid-19.Biochem. Pharmacol.202311598310.1016/j.bcp.2023.115983 38081371
    [Google Scholar]
11. FiorucciS. UrbaniG. Role of mRAGEs and ACE2 in SARS-CoV-2-related inflammation.Recent Adv. Inflamm. Allergy Drug Discov.20221612410.2174/277227081601221018140453 36508263
    [Google Scholar]
12. VukovikjM. MelidouA. NannapaneniP. NormarkT. KrausA. BrobergE.K. Impact of SARS-CoV-2 variant mutations on susceptibility to monoclonal antibodies and antiviral drugs: A non-systematic review, April 2022 to October 2024.Euro Surveill.20253010240025210.2807/1560‑7917.ES.2025.30.10.2400252 40084420
    [Google Scholar]
13. VlaarA.P.J. WitzenrathM. van PaassenP. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.Lancet Respir. Med.202210121137114610.1016/S2213‑2600(22)00297‑1 36087611
    [Google Scholar]
14. GulickR.M. PauA.K. DaarE. National Institutes of health COVID-19 treatment guidelines panel: Perspectives and lessons learned.Ann. Intern. Med.2024177111547155710.7326/ANNALS‑24‑00464 39348691
    [Google Scholar]
15. HorbyP. LimW.S. EmbersonJ.R. Dexamethasone in hospitalized patients with Covid-19.N. Engl. J. Med.2021384869370410.1056/NEJMoa2021436 32678530
    [Google Scholar]
16. AbaniO. AbbasA. AbbasF. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): A randomised, controlled, open-label, platform trial.Lancet2023401103871499150710.1016/S0140‑6736(23)00510‑X 37060915
    [Google Scholar]